Your browser doesn't support javascript.
loading
Efficacy and safety of liraglutide compared to sulphonylurea during Ramadan in patients with type 2 diabetes (LIRA-Ramadan): a randomized trial.
Azar, S T; Echtay, A; Wan Bebakar, W M; Al Araj, S; Berrah, A; Omar, M; Mutha, A; Tornøe, K; Kaltoft, M S; Shehadeh, N.
Afiliación
  • Azar ST; Dept. of Internal Medicine, American University of Beirut Medical Centre, Beirut, Lebanon. sazar@aub.edu.lb.
  • Echtay A; Dept. of Internal Medicine, Rafik Hariri University, Beirut, Lebanon.
  • Wan Bebakar WM; Dept. of Medicine, Universiti Sains Malaysia, Penang, Malaysia.
  • Al Araj S; Obaidulla Hospital, Ras al-Khairmah, United Arab Emirates.
  • Berrah A; Dept. of Medicine, University Hospital Bab El Oued, Algiers, Algeria.
  • Omar M; Dept. of Diabetes and Endocrinology, University of KwaZulu-Natal, KwaZulu-Natal, Republic of South Africa.
  • Mutha A; Diabetes Care & Research Centre, Nagpur, India.
  • Tornøe K; Medical & Science, GLP-1 & Obesity, Novo Nordisk A/S, Copenhagen, Denmark.
  • Kaltoft MS; Medical & Science, GLP-1 & Obesity, Novo Nordisk A/S, Copenhagen, Denmark.
  • Shehadeh N; Pediatric Diabetes Unit at Meyer Children's Hospital, Rambam Medical Centre and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel.
Diabetes Obes Metab ; 18(10): 1025-33, 2016 10.
Article en En | MEDLINE | ID: mdl-27376711
AIMS: Compare effects of liraglutide 1.8 mg and sulphonylurea, both combined with metformin, on glycaemic control in patients with type 2 diabetes (T2D) fasting during Ramadan. MATERIALS AND METHODS: In this up to 33-week, open-label, active-controlled, parallel-group trial, adults [glycated haemoglobin (HbA1c) 7%-10% (53-86 mmol/mol); body mass index ≥20 kg/m(2) ; intent to fast] were randomized (1:1) ≥10 weeks before Ramadan to either switch to once-daily liraglutide (final dose 1.8 mg) or continue pre-trial sulphonylurea at maximum tolerated dose, both with metformin. PRIMARY ENDPOINT: change in fructosamine, a validated marker of short-term glycaemic control, during Ramadan. RESULTS: Similar reductions in fructosamine levels were observed for both groups during Ramadan [liraglutide (-12.8 µmol/L); sulphonylurea (-16.4 µmol/L); estimated treatment difference (ETD) 3.51 µmol/L (95% CI: -5.26; 12.28); p = 0.43], despite lower fructosamine levels in the liraglutide group at start of Ramadan. Fewer documented symptomatic hypoglycaemic episodes were reported in liraglutide-treated (2%, three subjects) versus sulphonylurea-treated patients (11%, 18 subjects). No severe hypoglycaemic episodes were reported by either group. Body weight decreased more during Ramadan with liraglutide (ETD: -0.54 kg; 95% CI: -0.94;-0.14; p = 0.0091). The proportion of patients reporting adverse events was similar between groups. Liraglutide led to greater HbA1c reduction [ETD: -0.59% (-6.40 mmol/mol), 95% CI: -0.79; -0.38%; -8.63; -4.17 mmol/mol; p < 0.0001]. CONCLUSIONS: Despite lower fructosamine levels and body weight at the beginning of Ramadan, use of liraglutide showed similar glycaemic improvements, fewer hypoglycaemic episodes and greater body weight reduction compared with sulphonylurea. LIRA-Ramadan provides evidence for liraglutide being safe and efficacious for management of T2D during Ramadan fasting.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Compuestos de Sulfonilurea / Ayuno / Diabetes Mellitus Tipo 2 / Liraglutida / Hipoglucemiantes / Islamismo / Metformina Tipo de estudio: Clinical_trials Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Diabetes Obes Metab Asunto de la revista: ENDOCRINOLOGIA / METABOLISMO Año: 2016 Tipo del documento: Article País de afiliación: Líbano

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Compuestos de Sulfonilurea / Ayuno / Diabetes Mellitus Tipo 2 / Liraglutida / Hipoglucemiantes / Islamismo / Metformina Tipo de estudio: Clinical_trials Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Diabetes Obes Metab Asunto de la revista: ENDOCRINOLOGIA / METABOLISMO Año: 2016 Tipo del documento: Article País de afiliación: Líbano
...